Cyclin D as a therapeutic target in cancer
The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Abstract
Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression. The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target. Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Failure to modify cyclin D1 on T286 leads to aberrant nuclear accumulation of the protein, premature S phase entry, and enhanced cellular proliferation that drives tumorigenesis (17).”
From A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21 (2023) · cites this paper as [17]
In the citing paper
“Possibly, CCND1 amplification and CDKN2A loss may contribute to determining response to letrozole alone”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [68]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“The deregulation of cyclin expression or CDK activation can directly lead to some of the hallmarks of cance”
BackgroundComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 1×
“A second well-described non-catalytic role of cyclin D is the sequestration of p21 and p27 by cyclin D–CDK4/CDK6, leading to the indirect activation of CDK2 (REF”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“It may also be possible to identify low-molecular-mass inhibitors of cyclin–CDK substrate interactions using high-throughput screens that are similar to those used for the discovery and preclinical testing of inhibitors of MDM2–p53 binding (nutlins”
MethodThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“by causing proliferation that is independent of normal extracellular cues, or by over-riding checkpoints that ensure genomic integrity and stabilit”
BackgroundFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387 · cited 1×
“Given the increasingly routine clinical use of specific kinase inhibitor”
BackgroundmTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322 · cited 1×
“In Phase II clinical trials mTOR inhibitors were particularly effective in MCL, which is characterized by almost universal overexpression of cyclin D1, although this may not be accompanied by a reduction in cyclin D1 expression (reviewed in REF”
BackgroundBiological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Self-citation
Cited by
Items 201–300 of 1,000
Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs
Anderson, N. A., Cryan, J., Ahmed, A., Dai, H., McGonagle, G. A., Rozier, C., & Benowitz, A. B. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127106 · Cited by 69
Yuan, Y., Fan, Y., Gao, Z., Sun, X., Zhang, H., Wang, Z., Cui, Y., Song, W., Wang, Z., Zhang, F., et al. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0056 · Cited by 76
“Cyclin D1 is an unstable and short-lived protein whose stability is mainly modulated by a ubiquitination-mediated and proteasome-dependent pathway 49,50 .”
Whiteway, S. L., Harris, P. S., Venkataraman, S., Alimova, I., Birks, D. K., Donson, A. M., Foreman, N. K., & Vibhakar, R. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1000-7 · Cited by 68
“PD0332991 is an orally available small molecule inhibitor that targets the kinase activity of CDK4 and CDK6 [9].”
BackgroundInfluentialSeçme, M., Eroğlu, C., Dodurga, Y., & Bağcı, G. (2016) · Gene · doi:10.1016/j.gene.2016.03.038 · Cited by 69
miR-708-5p: a microRNA with emerging roles in cancer
Monteleone, N. J., & Lutz, C. S. (2017) · Oncotarget · doi:10.18632/oncotarget.19772 · Cited by 70
“All of these proteins have profound pro-oncogenic roles in survival (AKT1, BCL-2, PARP-1) [138, 139], proliferation (cyclin D1, AKT1, EZH2) [140], DNA repair (EZH2) [141], and invasion (MMP-2) [142].”
BackgroundCyclin D/CDK4/6 activity controls G1 length in mammalian cells
Dong, P., Zhang, C., Parker, B., You, L., & Mathey-Prévôt, B. (2018) · PLoS ONE · doi:10.1371/journal.pone.0185637 · Cited by 73
Functional and pathologic association of aminoacyl-tRNA synthetases with cancer
Sung, Y., Yoon, I., Han, J. M., & Kim, S. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00765-5 · Cited by 79
Papadimitriou, M., Pazaiti, A., Iliakopoulos, K., Markouli, M., Michalaki, V., & PAPADIMITRIOU, C. A. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119346 · Cited by 78
Bisteau, X., Paternot, S., Colleoni, B., Ecker, K., Coulonval, K., De Groote, P., Declercq, W., Hengst, L., & Roger, P. P. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003546 · Cited by 65
“CDK4/6 activity is deregulated through various mechanisms in many human tumors [18,19].”
BackgroundKang, J., Kim, W. J., Lee, S. Y., Kwon, D., Chun, J., Son, B., Kim, E., Lee, J.-M., Youn, H., & Youn, B. (2016) · Oncogene · doi:10.1038/onc.2016.328 · Cited by 68
El‐Sayed, W. A., Alminderej, F. M., Mounier, M. M., Nossier, E. S., Saleh, S. M., & Kassem, A. F. (2022) · Molecules · doi:10.3390/molecules27072047 · Cited by 75
“CDK-2 occupies a major part in cell cycle regulation including cell cycle propagation, differentiation, neuronal function and apoptosis [14,15].”
BackgroundTumour selective targeting of cell cycle kinases for cancer treatment
Aarts, M., Linardopoulos, S., & Turner, N. C. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.03.012 · Cited by 78
“CDK4/6 as a tumour selective target In normal cells, commitment to the cell cycle is controlled by cyclin D–CDK4/6 at the restriction point [3] (Figure 2).”
BackgroundCyclin D degradation by E3 ligases in cancer progression and treatment
Qie, S., & Diehl, J. A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.012 · Cited by 72
Tominaga, T., Shimada, R., Okada, Y., Kawamata, T., & Kibayashi, K. (2019) · PLOS ONE · doi:10.1371/journal.pone.0213673 · Cited by 66
LINE-1 Methylation Level and Patient Prognosis in a Database of 208 Hepatocellular Carcinomas
Harada, K., Baba, Y., Ishimoto, T., Chikamoto, A., Kosumi, K., Hayashi, H., Nitta, H., Hashimoto, D., Beppu, T., & Baba, H. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4134-3 · Cited by 71
“CDK6, a member of the serine–threonine kinases family, and cyclin D1 jointly inactivate the retinoblastoma protein, causing a promotion of cellular proliferation by regulating G1–S-phase progression.(49) Additionally, CDK6 is a critical player in carcinogenesis via controlling cellcycle progression in HCC.”
BackgroundArumugam, A., Agullo, P. A., Boopalan, T., Nandy, S., Lopez, R., Gutierrez, C., Narayan, M., & Lakshmanaswamy, R. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26604 · Cited by 66
“Overexpression of cyclin D1, Cdk4, and Cdk6 could contribute to loss of normal cell cycle control, leading to tumorigenesis.(34) Early studies reported cyclin D1 gene amplification in 10–15% of mammary carcinomas.”
BackgroundInfluentialLu, J., Lin, Y., Chang, J., Yeh, K., Chen, R.-M., Tsai, J., Su, W., & Hu, R. (2013) · Medical Oncology · doi:10.1007/s12032-012-0379-5 · Cited by 69
Xu, Y., Shi, Y., Qi, Y., Liu, X., Yan, B., Chen, L., Tao, Y., & Cao, Y. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-90 · Cited by 67
“Regulation of the cyclin D1 protein level is one of the critical aspects in cell proliferation and tumor development [49], indicating that cyclin D1 may be regarded as a therapeutic target in cancer [50].”
BackgroundLi, X., Song, Y., Zhang, P., Zhu, H., Chen, L., Xiao, Y., & Xing, Y. (2015) · Tumor Biology · doi:10.1007/s13277-015-4655-9 · Cited by 70
Chowdhary, M., Sen, N., Chowdhary, A., Usha, L., Cobleigh, M., Wang, D., Patel, K. R., Barry, P. N., & Rao, R. D. (2019) · Advances in Radiation Oncology · doi:10.1016/j.adro.2019.03.011 · Cited by 69
“The median time interval from blood draw and RT was 12 days (0-40) and 8 days (1-47) for pre- and postvalues, respectively.”
BackgroundCyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities
Zabihi, M., Lotfi, R., Yousefi, A., & Bashash, D. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04135-6 · Cited by 67
“Based on sequencing, CDKs are categorized into “cell cycle-related CDKs” including CDK1, − 2, − 4, − 6, and “transcriptional CDKs” consisting of CDK7, -8,-9, -11, -12, -13, -19, and -20 (Wood and Endicott 2018; Malumbres and Barbacid 2009; Bose et al. 2013; Musgrove et al. 2011).”
SHR and SCR coordinate root patterning and growth early in the cell cycle
Winter, C. M., Székely, P., Popov, V., Belcher, H., Carter, R., Jones, M., Fraser, S. E., Truong, T. V., & Benfey, P. N. (2024) · Nature · doi:10.1038/s41586-023-06971-z · Cited by 64
“Perturbation of the CYCLIN D–RBR–E2F pathway is estimated to occur during the development of nearly all cancers 47–51 , and defects in division plane orientation and formative division have recently been implicated in the genesis of breast and other cancers 7,8 .”
Li‐Weber, M. (2014) · International Journal of Cancer · doi:10.1002/ijc.29013 · Cited by 72
“Many cell-cycle-regulating proteins are short-living proteins, e.g. the cyclin dependent kinase 4 (CDK4), CDK6, cyclin D, Cdc25A and Cdc25B.25,43,44 These proteins are often over-expressed in human cancers to support demands of fast growth.25,43,44 In particular, over-expression of Cdc25A often correlates with more ag…”
BackgroundCDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer
Dai, M., Zhang, C., Ali, A., Hong, X., Tian, J., Lo, C., Fils-Aimé, N., Burgos, S. A., Ali, S., & Lebrun, J. J. (2016) · Scientific Reports · doi:10.1038/srep35383 · Cited by 65
Ye, L., Mayerle, J. V., Ziesch, A., Reiter, F. P., Gerbes, A. L., & Toni, E. N. D. (2019) · Cell Death Discovery · doi:10.1038/s41420-019-0165-7 · Cited by 71
Intermittent hypoxia exacerbates tumor progression in a mouse model of lung cancer
Kang, H. S., Kwon, H. Y., Kim, I. K., Ban, W. H., Kim, S. W., Kang, H. H., Yeo, C. D., & Lee, S. H. (2020) · Scientific Reports · doi:10.1038/s41598-020-58906-7 · Cited by 67
Li, N., Tang, A., Huang, S., Li, Z., Li, X., Shen, S., Ma, J., & Wang, X. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1664-0 · Cited by 63
“According to our results, miR-126 inhibited HT-29 cells proliferation, invasion and induced G1/S phase arrest, and we determined the expression of CCND1, CCND2, MMP2 and MMP9, which are well documental with cell proliferation, invasion and metastasis also down-regulated by miR-126 [43, 44].”
BackgroundBartkowiak-Wieczorek, J., Jaros, A., Gajdzińska, A., Wojtyła-Buciora, P., Szymański, I., Szymaniak, J., Janusz, W., Walczak, I., Jonaszka, G., & Bienert, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158167 · Cited by 70
“The mitogenic effects of oestrogens are particularly evident during the transition from G1 to S phase, during which critical effectors of oestrogen action are c-Myc and cyclin D1 [201,202].”
BackgroundTrzoss, L., Fukuda, T., Costa-Lotufo, L. V., Jimenez, P. C., Clair, J. J. L., & Fenical, W. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410932111 · Cited by 64
“3F), proteins whose cyclin-dependent kinase complexes are essential for entry into G1 (19).”
BackgroundCyclin D1 Represses Gluconeogenesis via Inhibition of the Transcriptional Coactivator PGC1α
Bhalla, K., Liu, W.-J., Thompson, K. N., Anders, L., Devarakonda, S., Dewi, R. E., Buckley, S., Hwang, B., Polster, B. M., Dorsey, S. G., et al. (2014) · Diabetes · doi:10.2337/db13-1283 · Cited by 66
“The classic function of cyclin D1 is regulation of the cell cycle (13,14).”
BackgroundPan, Y., Huang, J., Xing, R., Yin, X., Cui, J., Li, W., Yu, J. Q., & Lu, Y. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-173 · Cited by 63
“Its abundance will lead to oncogenic activation in stomach [37,38].”
α3 Chains of type V collagen regulate breast tumour growth via glypican-1
Huang, G., Ge, G., Izzi, V., & Greenspan, D. S. (2017) · Nature Communications · doi:10.1038/ncomms14351 · Cited by 66
“Also consistent with lower KO/PyMT proliferative activity were lowered levels of CDK6 and CDK4, which bind and are stabilized/activated by cyclin D 19,20 (Fig.”
Chen, L., & Pan, J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13836 · Cited by 60
“Rb phosphorylation facilitates the release of Rb from E2F transcription factor, enabling E2F to transcribe the genes that are required for cell cycle progression from the G1 to the S phase and ultimately for cellular proliferation (Musgrove et al., 2011; Reynolds et al., 2014).”
BackgroundOxymatrine inhibits non–small cell lung cancer via suppression of EGFR signaling pathway
Li, W., Yu, X., Tan, S., Liu, W., Zhou, L. Q., & Liu, H. (2017) · Cancer Medicine · doi:10.1002/cam4.1269 · Cited by 65
“may contribute to cyclin D1 expression [40].”
BackgroundKo, J., Um, J., Lee, S., Yang, W. M., Sethi, G., & Ahn, K. S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28456 · Cited by 67
“A number of other tumors such as breast, colon, gastric, ovarian, and renal cancers can arise and grow in the vicinity of adipocytes (Nieman et al., 2013).”
BackgroundDing, Z., Li, R., Zhang, Q., Wang, Y., Jiang, Y., Meng, Q., Xi, Q., & Wu, G. (2019) · Cancer Medicine · doi:10.1002/cam4.2152 · Cited by 67
Wang, W., Li, D., Xu, Q., Cheng, J., Yu, Z., Li, G., Qiao, S., Pan, J., Wang, H., Shi, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45353-5 · Cited by 64
miR-340 inhibits glioblastoma cell proliferation by suppressing CDK6, cyclin-D1 and cyclin-D2
Li, X., Gong, X., Chen, J., Zhang, J., Sun, J., & Guo, M. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.03.088 · Cited by 64
To, C., Ringelberg, C. S., Royce, D. B., Williams, C. R., Risingsong, R., Sporn, M. B., & Liby, K. T. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv061 · Cited by 63
“For instance, Mapk9 and Cyclin D are important players in cell proliferation (62,63).”
BackgroundProgress with palbociclib in breast cancer: latest evidence and clinical considerations
Rocca, A., Schirone, A., Maltoni, R., Bravaccini, S., Cecconetto, L., Farolfi, A., Bronte, G., & Andreis, D. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016677961 · Cited by 68
Eisfeld, A.-K., Kohlschmidt, J., Schwind, S., Nicolet, D., Blachly, J. S., Orwick, S. J., Shah, C., Bainazar, M. A., Kroll, K. W., Walker, C. J., et al. (2016) · Leukemia · doi:10.1038/leu.2016.332 · Cited by 63
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer
Shah, A. N., & Cristofanilli, M. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0443-7 · Cited by 71
Magiera‐Mularz, K., Tomala, M. D., Kubica, K., Cesare, V. D., Trost, M., Zieba, B. J., Kachamakova‐Trojanowska, N., Leś, M., Dubin, G., Holak, T. A., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.03.002 · Cited by 62
“Cyclin D1 was reported to function as an oncoprotein, providing the cancer cell not only with the advantage of mitogen-independent proliferation but also modulation of processes such as angiogenesis and DNA-damage response (Bartkova et al., 1995;Musgrove et al., 2011).”
Backgroundvan Harten, A. M., Buijze, M., van der Mast, R., Rooimans, M. A., Kemp, S. R. M., Bachas, C., Brink, A., van Walsum, M., Wolthuis, R. M. F., & Brakenhoff, R. H. (2019) · Oncogenesis · doi:10.1038/s41389-019-0147-x · Cited by 64
CDK4/6 inhibition in early and metastatic breast cancer: A review
de Groot, A. F., Kuijpers, C. C. H. J., & Kroep, J. R. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.09.003 · Cited by 69
To Cycle or Fight—CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity
Ameratunga, M., Kipps, E., Okines, A. F. C., & Lopez, J. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1999 · Cited by 62
“The Cyclin D1 gene (CCND1) represents the second most frequently amplified locus among all human cancer types (20), with the highest prevalence in welldifferentiated and dedifferentiated liposarcoma (21), glioblastomas (22), breast cancer (23–25), non–small cell lung cancer (NSCLC), endometrial cancers, and pancreatic…”
BackgroundPredicting and Overcoming Chemotherapeutic Resistance in Breast Cancer
Chun, K., Park, J. H., & Fan, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_4 · Cited by 64
Guo, Z., Tang, Y., Wang, S., Huang, Y., Chi, Q., Xu, K., & Xue, L. (2023) · BioFactors · doi:10.1002/biof.2031 · Cited by 70
Huang, O., Zhang, W., Zhi, Q., Xue, X., Liu, H., Shen, D., Geng, M., Xie, Z., & Jiang, M. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214554881 · Cited by 60
“Cyclin D1 binds with CDK4, forming cyclin D1/CDK4 complex, and initiates the phosphorylation of RB, disrupting RBmediated transcriptional repression of target genes involved in cell progression through G1.”
Role of cyclins in controlling progression of mammalian spermatogenesis
Wolgemuth, D. J., Manterola, M., & Vasileva, A. (2013) · The International Journal of Developmental Biology · doi:10.1387/ijdb.130047av · Cited by 64
“Cyclin D1, as well D2 and D3 are frequently deregulated in cancers such as leukemia, breast, prostate and hepatocarcinoma, representing a biomarker for disease progression (Musgrove et al., 2011).”
The therapeutic potential of cell cycle targeting in multiple myeloma
Maes, A., Menu, E., Veirman, K. D., Maes, K., Vanderkerken, K., & Bruyne, E. D. (2017) · Oncotarget · doi:10.18632/oncotarget.18765 · Cited by 63
“Deregulation of cyclin D genes is an uniform event in MM patients and results in an aberrant cell division [3, 16].”
BackgroundLundberg, A., Lindström, L. S., Li, J., Harrell, J. C., Darai‐Ramqvist, E., Sifakis, E. G., Foukakis, T., Perou, C. M., Czene, K., Bergh, J. C. S., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1121-4 · Cited by 59
“It has been previously been suggested that CCND1 amplification could serve as a biomarker for the prediction of response to cyclin-dependent kinase 4/6 inhibitors [39].”
BackgroundShrotriya, S., Deep, G., Gu, M., Kaur, M., Jain, A. K., Inturi, S., Agarwal, R., & Agarwal, C. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs019 · Cited by 58
Chd5 Requires PHD-Mediated Histone 3 Binding for Tumor Suppression
Paul, S., Kuo, A. J., Schalch, T., Vogel, H. S., Joshua‐Tor, L., McCombie, W. R., Gozani, O., Hammell, M., & Mills, A. A. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.12.009 · Cited by 58
“Chd5 to transcriptionally modulate its targets, including genes that have been implicated in Wnt signaling, chromatin remodeling, and cell-cycle regulation, highlighting Chd5’s role in pathways that were previously implicated in tumor suppression (Hers et al., 2011; Musgrove et al., 2011; Yadav et al., 2009; Yao et al…”
BackgroundHuang, W., Su, H.-H., Fang, L.-W., Wu, S., & Liou, C. (2019) · Cells · doi:10.3390/cells8030218 · Cited by 58
“Cyclin D could regulate the transition from G1 phase to S phase, and p21, a cyclin-dependent protein kinase, could regulate cyclin D expression [43,44].”
BackgroundMETTL7B Is Required for Cancer Cell Proliferation and Tumorigenesis in Non-Small Cell Lung Cancer
Liu, D., Li, W., Zhong, F., Yin, J., Zhou, W., Li, S., Sun, X., Xu, J., Li, G., Wen, Y., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00178 · Cited by 64
“In addition, CCND1 overexpression causes a number of potentially oncogenic responses in experimental models and is associated with poor patient outcome (Musgrove et al., 2011).”
BackgroundRelevance of pRB Loss in Human Malignancies
Mandigo, A. C., Tomlins, S. A., Kelly, W. K., & Knudsen, K. E. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1565 · Cited by 59
Unraveling molecular networks in thymic epithelial tumors: deciphering the unique signatures
Zhang, X., Zhang, P., Cong, A., Feng, Y., Chi, H., Xia, Z., & Tang, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264325 · Cited by 57
“Perturbations in CDKN2A can potentially instigate the activation of cyclin-dependent kinases, thereby disrupting the finely tuned regulation of the cell cycle (38).”
BackgroundCell cycle machinery in oncology: A comprehensive review of therapeutic targets
Cavalu, S. D., Abdelhamid, A. M., Saber, S., Elmorsy, E. A., Hamad, R. S., Abdel‐Reheim, M. A., Yahya, G., & Salama, M. M. (2024) · The FASEB Journal · doi:10.1096/fj.202400769r · Cited by 65
“27”
Su, B.-H., Qu, J., Song, M. S., Huang, X., Hu, X.-M., Xie, J. W., Zhao, Y., Ding, L.-C., She, L., Chen, J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2321 · Cited by 57
“Among these validated target genes, BCL-2 is a well-known anti-apoptotic gene [26], and CCND1 is a cell cycle-related gene [27], consistent with the increased apoptotic cells (Fig.”
Zhang, Y., Liu, C., Duan, X., Ren, F., Li, S., Jin, Z. H., Wang, Y., Feng, Y., Liu, Z., & Chang, Z. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.560979 · Cited by 59
“of Cyclin D1 has been observed in the development of cancers, caused by dysfunction or abnormal expression of many regulators (32).”
BackgroundFan, Y., Fang, X., Tajima, A., Geng, X., Ranganathan, S., Dong, H. H., Trucco, M., & Sperling, M. A. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00218 · Cited by 60
“Over expression of this gene may alter cell-cycle progression, has been observed in various tumors, and possibly contributed to tumor formation in our GHRLD mice (39).”
BackgroundRajamanickam, S., Subbarayalu, P., Gorthi, A., Timilsina, S., Onyeagucha, B. C., Kovalskyy, D., Ivanov, D., Hanes, M. A., Vadlamudi, R. K., Chen, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2535 · Cited by 58
“Because Rad51 is a direct transcriptional target of FoxM1 (31), is functionally linked with Skp2 (39) and physically and functionally interactswith cyclinD1 (26), it is likely that the FoxM1–cyclin D1–Skp2–RAD51 signaling cascade is a central component mediating IB's effect on HR (Fig.”
BackgroundRelevance of chromosomal band 11q13 in oral carcinogenesis: An update of current knowledge
Ramos‐García, P., Ruiz‐Ávila, I., Montoya, J. A. G., Ayén, Á., González‐Ruiz, L., Navarro‐Triviño, F. J., & González‐Moles, M. Á. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.04.016 · Cited by 59
Saghafi, T., Taheri, R. A., Parkkila, S., & Emameh, R. Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122939 · Cited by 58
“3, MUDENG, AK056098, and AK294004 [68,69].”
Li, X., Zhang, B., Wang, H., Zhao, X., Zhang, Z., Ding, G., & Wei, F. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01846-w · Cited by 62
“Furthermore, in addition to its role in cell cycle progression, cyclin D3 imparts signi cant effects on PPARγ activity and subsequently on adipogenesis (44, 45).”
BackgroundTRIM31 is downregulated in non-small cell lung cancer and serves as a potential tumor suppressor
Li, H., Zhang, Y., Zhang, Y., Bai, X., Yang, P., & He, P. (2014) · Tumor Biology · doi:10.1007/s13277-014-1763-x · Cited by 56
“In addition, Cyclin D1 could serve as a potential target for therapeutic invention [14, 15].”
BackgroundInhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy
Lyou, Y., Habowski, A. N., Chen, G. T., & Waterman, M. L. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13963 · Cited by 58
“However, Wnt target genes that drive proliferation such as CMYC and CCND1 are often viewed as un-druggable since they lack enzymatic activity that can be inhibited and because they are required in non-malignant cells (Musgrove et al., 2011; Rennoll and Yochum, 2015; Koh et al., 2016).”
BackgroundLv, Y., Yang, H., Ma, X., & Wu, G. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0915-x · Cited by 56
Xu, T., Ruan, H., Gao, S., Liu, J., Liu, Y., Song, Z., Cao, Q., Wang, K., Bao, L., Liu, D., et al. (2020) · Aging · doi:10.18632/aging.102714 · Cited by 65
“CCND1 (cyclin D1), a member of the highly conserved cyclin family, acts as a regulator of CDK kinases for mediating cell cycle [66, 67].”
BackgroundCurrent Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
Wu, Y., Zhang, Y., Pi, H., & Sheng, Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s250632 · Cited by 59
Deubiquitinase USP5 promotes non-small cell lung cancer cell proliferation by stabilizing cyclin D1
Zhang, Z., Cui, Z., Xie, Z., Li, C., Xu, C., Guo, X. N., Yu, J. Z., Chen, T., Facchinetti, F., Bohnenberger, H., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-767 · Cited by 60
“Since CCND1, as a member of the D-type cyclin subfamily, is vital for cell cycle progression (9-11), we hypothesized that the USP5-elicited regulatory effect on CCND1 expression would affect cell cycle transition in NSCLC cells.”
InfluentialJadamba, E., & Shin, M. (2016) · BioMed Research International · doi:10.1155/2016/7147039 · Cited by 61
Dietary Polyphenols and Their Effects on Cell Biochemistry and Pathophysiology 2013
Maraldi, T., Vauzour, D., & Angeloni, C. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/576363 · Cited by 56
Reviewing cancer’s biology: an eclectic approach
DIORI, I. K., & Şanlıer, Ş. H. (2021) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-021-00088-y · Cited by 64
Lai, V. K., Ashraf, M., Jiang, S., & Haider, K. H. (2012) · Cell Cycle · doi:10.4161/cc.11.4.19211 · Cited by 55
pH-Controlled multiple-drug delivery by a novel antibacterial nanocomposite for combination therapy
Zeynabad, F. B., Salehi, R., Alizadeh, E., Kafil, H. S., Hassanzadeh, A. M., & Mahkam, M. (2015) · RSC Advances · doi:10.1039/c5ra22784d · Cited by 57
Cyclin D mediates tolerance of genome-doubling in cancers with functional p53
Crockford, A., Zalmas, L., Gronroos, E. C., Dewhurst, S. M., McGranahan, N., Cuomo, M. E., Encheva, V., Snijders, A. P., Begum, J., Purewal, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw612 · Cited by 56
“A non-catalytic role of cyclin D1 involves the sequestration and, subsequently, inhibition p21 [15,21,22].”
BackgroundInfluentialExpression and Therapeutic Potential of SOX9 in Chordoma
Chen, H., Garbutt, C. C., Spentzos, D., Choy, E., Hornicek, F. J., & Duan, Z. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0177 · Cited by 54
“The overexpression of cyclin D1 gives it a well-documented reputation as an oncogene heavily involved in the progression of various cancer types as well as a link to poor prognosis (40).”
BackgroundCDCA8 is a key mediator of estrogen-stimulated cell proliferation in breast cancer cells
Bu, Y., Shi, L.-B., Yu, D., Liang, Z., & Li, W. (2019) · Gene · doi:10.1016/j.gene.2019.04.006 · Cited by 54
Personalized targeted therapy for esophageal squamous cell carcinoma
Kang, X., Chen, K., Li, Y., Li, J., D'Amico, T. A., & Chen, X. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i25.7648 · Cited by 58
Genomic DNA copy number alterations from precursor oral lesions to oral squamous cell carcinoma
Salahshourifar, I., Vincent–Chong, V. K., Kallarakkal, T. G., & Zain, R. B. (2014) · Oral Oncology · doi:10.1016/j.oraloncology.2014.02.005 · Cited by 54
“CCND1 is a proto-oncogene that controlsG1/S transition in the cell cycle and shows amplification in a variety of cancers [70].”
BackgroundMetformin induces degradation of cyclin D1 via AMPK/GSK3β axis in ovarian cancer
Gwak, H., Kim, Y., An, H., Dhanasekaran, D. N., & Song, Y. S. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22498 · Cited by 53
Diffuse and strong cyclin D1 immunoreactivity in clear cell sarcoma of the kidney
Mirković, J., Calicchio, M. L., Fletcher, C. D. �., & Pérez‐Atayde, A. R. (2015) · Histopathology · doi:10.1111/his.12641 · Cited by 57
“Cyclin D1 is a G1-specific cyclin that associates with CDK4, promotes restriction point progression during the G1 phase, and is frequently altered in cancers such as mantle cell lymphoma, non-smalllung cancer, and carcinomas of the breast, head and neck, and oesophagus.(9) A number of mechanisms promote cyclin D1 over…”
BackgroundYB ‐1 promotes transcription of cyclin D1 in human non‐small‐cell lung cancers
Harada, M., Kotake, Y., Ohhata, T., Kitagawa, K., Niida, H., Matsuura, S., Funai, K., Sugimura, H., Suda, T., & Kitagawa, M. (2014) · Genes to Cells · doi:10.1111/gtc.12150 · Cited by 58
Koo, K. H., & Kwon, H. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0100-x · Cited by 53
Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma
Rihani, A., Vandesompele, J., Speleman, F., & Maerken, T. V. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0224-y · Cited by 54
“Targeting the cyclin D1‑CDK4/CDK6 complex with palbociclib Targeting cyclin D1 with small molecule compounds is currently not possible.”
BackgroundMethodInfluentialLi, Y., Jin, K., Bunker, E. N., Zhang, X., Luo, X., Liu, X., & Hao, B. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708677115 · Cited by 58
“Cyclin D1, the most intensively investigated D-type cyclin, is frequently deregulated in cancer, and its overexpression directly contributes to genomic instability and tumorigenesis (5).”
BackgroundEl‐Sayed, W. A., Alminderej, F. M., Mounier, M. M., Nossier, E. S., Saleh, S. M., & Kassem, A. F. (2022) · Molecules · doi:10.3390/molecules27175688 · Cited by 59
“Moreover, cyclin-dependent kinases (CDKs) are members of protein kinases that have an essential role in regulation of the sequential stages in the cell cycle [17].”
BackgroundMolecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms
Tafe, L. J., Muller, K. E., Ananda, G., Mitchell, T. N., Spotlow, V., Patterson, S. E., Tsongalis, G. J., & Mockus, S. M. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.11.008 · Cited by 54
Wang, Z., Zhang, H., Zhou, J., Zhang, X., Chen, L., Chen, K., & Huang, Z. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3171-y · Cited by 51
“According to the literatures [19, 20], the cell cycle progression is controlled by cyclins, cyclin-dependent kinase (CDK) and cyclin-dependent kinase inhibitors (CKIs).”
BackgroundZhang, Y., Huo, F., Wei, L., Gong, C., Pan, Y., Mou, J., & Pei, D. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0610-5 · Cited by 51
“Cyclin Ds that contain Cyclin D1, Cyclin D2 and Cyclin D3, are closely related G1 cyclins and are of particular importance to the cancer field [29].”
Tyagi, N., Deshmukh, S. K., Srivastava, S. K., Azim, S., Ahmad, A., AL-Ghadhban, A., Singh, A. P., Carter, J. E., Wang, B., & Singh, S. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0219 · Cited by 55
“amplification is reportedonly in 25%cases (48) suggesting that its overexpression is likely regulated through other mechanisms in pancreatic cancers.”
BackgroundRoles of Tristetraprolin in Tumorigenesis
Park, J., Lee, T.-H., & Kang, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113384 · Cited by 54
“CCND1 binding with cyclin dependent kinase 4 (CDK4) or CDK6 is necessary for the G1/S transition [50].”
BackgroundThe Diverse Consequences of FOXC1 Deregulation in Cancer
Gilding, L. N., & Somervaille, T. C. P. (2019) · Cancers · doi:10.3390/cancers11020184 · Cited by 55
“Indeed, both of these putative FOXC1 targets are proto-oncogenes which contribute to cell cycle progression and are commonly deregulated in cancer [70,71].”
BackgroundXiong, Y., Li, T., Assani, G., Ling, H., Zhou, Q., Zeng, Y., Zhou, F., & Zhou, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108602 · Cited by 52
Liu, L., Tian, Q., Liu, J., Zhou, Y., & Yong, H. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28536 · Cited by 51
“CDK6 activation can facilitate cell cycle via the phosphorylation of its substrates.(27) CDK6 has been reported to be increased in various cancers.”
BackgroundThe Relationship between Estrogen-Related Signaling and Human Papillomavirus Positive Cancers
James, C. D., Morgan, I. M., & Bristol, M. L. (2020) · Pathogens · doi:10.3390/pathogens9050403 · Cited by 55
Different Approaches to Develop Nanosensors for Diagnosis of Diseases
Arndt, N., Nguyen, D. H. T., Zhang, R., Xu, Z. P., & Ta, H. T. (2020) · Advanced Science · doi:10.1002/advs.202001476 · Cited by 53
Long, Y., Wang, Z., Fan, J., Yuan, L., Tong, C., Zhao, Y., & Liu, B. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb00029b · Cited by 51
Metadata
- Authors
- Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L.
- Affiliations
- Garvan Institute of Medical Research (AU)
- Corresponding author
- Sutherland, Robert L.
- ORCID
- Caldon, C. Elizabeth
- Venue
- Nature Reviews Cancer
- Published
- 2011-07-07
- Volume
- 11
- Issue
- 8
- Pages
- 558-572
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2089655089
- Cited by
- 1,370
- References
- 190
- Citations by year
- 2026: 54 · 2025: 65 · 2024: 57 · 2023: 78 · 2022: 85 · 2021: 102 · 2020: 113 · 2019: 100 · 2018: 93 · 2017: 130 · 2016: 129 · 2015: 105 · 2014: 92 · 2013: 91 · 2012: 75
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- cyclin D1, cyclin D, cyclin-dependent kinases, CDK4, CDK6, oncogene deregulation, cancer therapy, therapeutic target, biomarkers, patient subgroup identification, tumor progression
- MeSH terms
- Humans, Neoplasms, Oncogenes, Polymorphism, Genetic, Cyclin D
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.